Cancer Discovery to present practice-changing research at AACR meeting

Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.

The debut sample issue will feature research that enhances the classification of prostate cancer and proposes a possible new therapy, introduces potential new targets for lung cancer, and redefines immunotherapy in breast cancer.

Co-editors in Chief Lewis Cantley, Ph.D., director of the Beth Israel Deaconess Medical Center and professor of Systems Biology at Harvard Medical School, and Jose Baselga, M.D., Ph.D., associate director and chief of the division of hematology/oncology at the Massachusetts General Hospital, will host a press conference on these studies and discuss the implications of the new journal for the field. This press conference will be held on Sunday, April 3 at 1:00 p.m. ET in Room W313 of the Orange County Convention Center.

"Cancer Discovery is poised to make major contributions to the growing body of knowledge. These papers are examples of the practice-changing research we can expect from this esteemed journal," said Cantley.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients